Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANUJA JHINGRAN and ANN H KLOPP.
ANUJA JHINGRAN
Connection Strength
6.322
ANN H KLOPP
  1. Big Data to the Rescue: Is there a benefit to combined-modality adjuvant therapy in endometrial cancer? Gynecol Oncol. 2016 06; 141(3):403-404.
    View in: PubMed
    Score: 0.579
  2. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys. 2013 May 01; 86(1):83-90.
    View in: PubMed
    Score: 0.468
  3. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023 11 13; 41(11):1945-1962.e11.
    View in: PubMed
    Score: 0.241
  4. Circulating neutrophils and tumor-associated myeloid cells function as a powerful biomarker for response to chemoradiation in locally advanced cervical cancer. Clin Transl Radiat Oncol. 2023 Mar; 39:100578.
    View in: PubMed
    Score: 0.229
  5. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
    View in: PubMed
    Score: 0.214
  6. Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. Gynecol Oncol. 2022 03; 164(3):550-557.
    View in: PubMed
    Score: 0.213
  7. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun Biol. 2021 02 22; 4(1):237.
    View in: PubMed
    Score: 0.201
  8. Clinical utility and value contribution of an MRI-positive line marker for image-guided brachytherapy in gynecologic malignancies. Brachytherapy. 2020 May - Jun; 19(3):305-315.
    View in: PubMed
    Score: 0.189
  9. Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 05 01; 107(1):163-171.
    View in: PubMed
    Score: 0.186
  10. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. Brachytherapy. 2020 Jul - Aug; 19(4):427-437.
    View in: PubMed
    Score: 0.184
  11. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019 11; 155(2):237-244.
    View in: PubMed
    Score: 0.182
  12. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
    View in: PubMed
    Score: 0.178
  13. Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer. Radiother Oncol. 2019 06; 135:58-64.
    View in: PubMed
    Score: 0.175
  14. Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):593-600.
    View in: PubMed
    Score: 0.168
  15. Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. Int J Gynecol Cancer. 2018 01; 28(1):114-121.
    View in: PubMed
    Score: 0.162
  16. Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol. 2018 01; 148(1):132-138.
    View in: PubMed
    Score: 0.160
  17. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):546-553.
    View in: PubMed
    Score: 0.149
  18. Comparison of Computed Tomography- and Magnetic Resonance Imaging-based Clinical Target Volume Contours at Brachytherapy for?Cervical Cancer. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):793-800.
    View in: PubMed
    Score: 0.146
  19. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct; 139(1):40-6.
    View in: PubMed
    Score: 0.136
  20. Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer. Brachytherapy. 2015 May-Jun; 14(3):385-9.
    View in: PubMed
    Score: 0.132
  21. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):357-62.
    View in: PubMed
    Score: 0.123
  22. Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol Oncol. 2013 Dec; 131(3):645-9.
    View in: PubMed
    Score: 0.117
  23. Anatomic distribution of fluorodeoxyglucose-avid para-aortic lymph nodes in patients with cervical cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1045-50.
    View in: PubMed
    Score: 0.115
  24. Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging. Int J Gynecol Cancer. 2012 Sep; 22(7):1203-7.
    View in: PubMed
    Score: 0.112
  25. Pilot study of a computed tomography-compatible shielded intracavitary brachytherapy applicator for treatment of cervical cancer. Pract Radiat Oncol. 2013 Apr-Jun; 3(2):115-23.
    View in: PubMed
    Score: 0.109
  26. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol. 2009 Oct; 115(1):6-11.
    View in: PubMed
    Score: 0.090
  27. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):226-36.
    View in: PubMed
    Score: 0.083
  28. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy. Brachytherapy. 2024 Mar-Apr; 23(2):123-135.
    View in: PubMed
    Score: 0.061
  29. Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement. Gynecol Oncol. 2024 Jan; 180:24-34.
    View in: PubMed
    Score: 0.061
  30. Comparing long-term sexual dysfunction across different uterine cancer treatment modalities. Brachytherapy. 2024 Jan-Feb; 23(1):1-9.
    View in: PubMed
    Score: 0.061
  31. Identifying the optimal deep learning architecture and parameters for automatic beam aperture definition in 3D radiotherapy. J Appl Clin Med Phys. 2023 Dec; 24(12):e14131.
    View in: PubMed
    Score: 0.060
  32. Patient Reported Outcomes for Women Undergoing Definitive Chemoradiation for Gynecologic Cancer: A Prospective Clinical Trial. Pract Radiat Oncol. 2023 Nov-Dec; 13(6):e538-e546.
    View in: PubMed
    Score: 0.060
  33. Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structure. BMC Cancer. 2022 Sep 01; 22(1):945.
    View in: PubMed
    Score: 0.056
  34. Impact of treatment modality on pelvic floor dysfunction among uterine cancer survivors. Int J Gynecol Cancer. 2022 Jun 09.
    View in: PubMed
    Score: 0.055
  35. Longitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical Cancer Treatment. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):e423-e433.
    View in: PubMed
    Score: 0.054
  36. Clinical Implementation and Initial Experience With a 1.5 Tesla MR-Linac for MR-Guided Radiation Therapy for Gynecologic Cancer: An R-IDEAL Stage 1 and 2a First in Humans Feasibility Study of New Technology Implementation. Pract Radiat Oncol. 2022 Jul-Aug; 12(4):e296-e305.
    View in: PubMed
    Score: 0.054
  37. Use of Specific Duodenal Dose Constraints During Treatment Planning Reduces Toxicity After Definitive Paraaortic Radiation Therapy for Cervical Cancer. Pract Radiat Oncol. 2022 May-Jun; 12(3):e207-e215.
    View in: PubMed
    Score: 0.053
  38. Emerging Use of Public-Private Partnerships in Public Radiotherapy Facilities in Nigeria. JCO Glob Oncol. 2021 08; 7:1260-1269.
    View in: PubMed
    Score: 0.052
  39. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One. 2021; 16(3):e0247905.
    View in: PubMed
    Score: 0.050
  40. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):413-424.
    View in: PubMed
    Score: 0.049
  41. Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations. Gynecol Oncol. 2020 08; 158(2):244-253.
    View in: PubMed
    Score: 0.048
  42. A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Support Care Cancer. 2021 Jan; 29(1):213-222.
    View in: PubMed
    Score: 0.047
  43. Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer. 2020 06 01; 126(11):2607-2613.
    View in: PubMed
    Score: 0.047
  44. Pelvic Insufficiency Fractures After External Beam Radiation Therapy for Gynecologic Cancers: A Meta-analysis and Meta-regression of 3929 Patients. Int J Radiat Oncol Biol Phys. 2020 03 01; 106(3):475-484.
    View in: PubMed
    Score: 0.046
  45. Detection of air gaps around the cylinder by postinsertion computed tomography in vaginal cuff brachytherapy: A prospective series, systematic review, and meta-analysis. Brachytherapy. 2019 Sep - Oct; 18(5):620-626.
    View in: PubMed
    Score: 0.045
  46. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. Brachytherapy. 2019 Jul - Aug; 18(4):445-452.
    View in: PubMed
    Score: 0.044
  47. Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecol Oncol. 2016 Dec; 143(3):552-557.
    View in: PubMed
    Score: 0.037
  48. Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy. Pract Radiat Oncol. 2017 May - Jun; 7(3):e165-e173.
    View in: PubMed
    Score: 0.037
  49. Isolated port-site metastases after minimally invasive hysterectomy for endometrial cancer: outcomes of patients treated with radiotherapy. Int J Gynecol Cancer. 2015 Jun; 25(5):869-74.
    View in: PubMed
    Score: 0.034
  50. Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: time to reconsider the FIGO staging system? Gynecol Oncol. 2015 Feb; 136(2):269-73.
    View in: PubMed
    Score: 0.033
  51. Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. Obstet Gynecol. 2014 Dec; 124(6):1098-1104.
    View in: PubMed
    Score: 0.033
  52. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):300-5.
    View in: PubMed
    Score: 0.029
  53. Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer. Pract Radiat Oncol. 2013 Jan-Mar; 3(1):e21-e28.
    View in: PubMed
    Score: 0.027
  54. Anatomic distribution of [(18)F] fluorodeoxyglucose-avid lymph nodes in patients with cervical cancer. Pract Radiat Oncol. 2013 Jan-Mar; 3(1):45-53.
    View in: PubMed
    Score: 0.027
  55. Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1331-6.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.